ACORQ vs. SCNI, PKBO, GMDAQ, WINT, ELOX, EVLO, OSA, OSAP, BLPH, and TIVC
Should you be buying Acorda Therapeutics stock or one of its competitors? The main competitors of Acorda Therapeutics include Scinai Immunotherapeutics (SCNI), Peak Bio (PKBO), Gamida Cell (GMDAQ), Windtree Therapeutics (WINT), Eloxx Pharmaceuticals (ELOX), Evelo Biosciences (EVLO), ProSomnus (OSA), ProSomnus (OSAP), Bellerophon Therapeutics (BLPH), and Tivic Health Systems (TIVC). These companies are all part of the "medical" sector.
Scinai Immunotherapeutics (NASDAQ:SCNI) and Acorda Therapeutics (NASDAQ:ACORQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.
Scinai Immunotherapeutics has higher earnings, but lower revenue than Acorda Therapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.
Scinai Immunotherapeutics has a net margin of 0.00% compared to Scinai Immunotherapeutics' net margin of -227.75%. Acorda Therapeutics' return on equity of 0.00% beat Scinai Immunotherapeutics' return on equity.
Scinai Immunotherapeutics and Acorda Therapeutics both received 0 outperform votes by MarketBeat users.
58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 12.7% of Acorda Therapeutics shares are held by institutional investors. 6.0% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 2.6% of Acorda Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Scinai Immunotherapeutics and Scinai Immunotherapeutics both had 1 articles in the media. Acorda Therapeutics' average media sentiment score of 0.25 beat Scinai Immunotherapeutics' score of -0.95 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.
Scinai Immunotherapeutics has a beta of 2.45, meaning that its stock price is 145% more volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.
Summary
Scinai Immunotherapeutics beats Acorda Therapeutics on 9 of the 11 factors compared between the two stocks.
Get Acorda Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACORQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACORQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ACORQ vs. The Competition
Acorda Therapeutics Competitors List
Related Companies and Tools
